STOCK TITAN
  1. Home
  2. News
  3. MSCLF

Satellos Bioscience Inc. - $MSCLF STOCK NEWS

Welcome to our dedicated page for Satellos Bioscience news (Ticker: $MSCLF), a resource for investors and traders seeking the latest updates and insights on Satellos Bioscience stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Satellos Bioscience's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Satellos Bioscience's position in the market.

News
Satellos Announces Management Team Update
Rhea-AI Summary
Satellos Bioscience Inc. announced the departure of their Chief Medical Officer, Alan K. Jacobs, and the engagement of Jordan Dubow, M.D., as the new Chief Medical Advisor. Dr. Dubow will lead the clinical trial strategy for the Company’s lead program in Duchenne muscular dystrophy. The CEO thanked Dr. Jacobs for his contributions and expressed excitement about working with Dr. Dubow. Satellos is a public biotech company developing small molecule therapeutic approaches for muscle diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Satellos Receives Conditional Approval to Graduate to the Toronto Stock Exchange
Rhea-AI Summary
Satellos Bioscience Inc. has received conditional approval from the Toronto Stock Exchange to graduate from the TSX Venture Exchange and to list its common shares on the TSX. The company aims to expand its reach to a broader range of global investors and is progressing its lead small molecule drug candidate for Duchenne muscular dystrophy through IND-enabling studies and GMP manufacturing, with clinical trials set to begin in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Satellos to Present at the Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Summary
Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) announces participation in the Piper Sandler 35th Annual Healthcare Conference. CEO Frank Gleeson and CFO Elizabeth Williams to present a corporate presentation and participate in one-on-one meetings. Webcast available for 90 days after the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.15%
Tags
conferences
News
Satellos Discloses Drug Target and Provides Development Update on Duchenne Muscular Dystrophy Program
Rhea-AI Summary
Satellos Bioscience Inc. (MSCL) Announces Duchenne Program Updates, Nominates SAT-3247 as Lead Drug Candidate, and Appoints Senior Vice President, Clinical Development Operations. The company is conducting IND-enabling studies and GMP manufacturing, filing patent applications for its drug target, and remains on track to initiate clinical development in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.7%
Tags
none
-
News
Satellos to Present at the Stifel 2023 Healthcare Conference
Rhea-AI Summary
Satellos Bioscience Inc., a biotech company focused on developing new small molecule therapeutic approaches for muscle diseases, will present at the Stifel 2023 Healthcare Conference in New York City. The company's CEO, Frank Gleeson, will give a corporate presentation and participate in one-on-one meetings. A webcast of the panel presentation will be available for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.2%
Tags
conferences
-
News
Satellos to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023
Rhea-AI Summary
Satellos Bioscience to participate in Cantor Fitzgerald Global Healthcare Conference 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
News
Satellos Bioscience Enters Into an Agreement with ICP Securities Inc. to Provide Market Making Services
Rhea-AI Summary
Satellos Bioscience Inc. has entered into an agreement with ICP Securities Inc. to provide market making services for its securities. The company will pay a service fee of $7,500 per month for four months. Satellos has also engaged Insight Capital Partners Inc. to provide capital markets advisory services and has granted stock options to Insight and its affiliates. Additionally, stock options have been granted to a Director, an Officer, and the Chief Financial Officer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.52%
Tags
none
-
News
Satellos Expands Leadership Team with New CFO Appointment
Rhea-AI Summary
Satellos Bioscience appoints Elizabeth Williams as CFO and Warren Whitehead transitions to Head of Corporate Strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.31%
Tags
management
-
News
Satellos Bioscience Announces Q2 2023 Financial Results and Operational Highlights
Rhea-AI Summary
Satellos Bioscience Inc. announced financial results for Q2 2023, with $48.7 million in cash and cash equivalents at June 30, 2023. The company attracted $55 million in equity financing from elite biotechnology institutional investors. Satellos received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA for SAT-3153, providing potential market exclusivity and other benefits. The company also closed an Equity Offering for gross proceeds of $55 million. Alan K. Jacobs was appointed as Chief Medical Officer. Net Loss, Comprehensive Loss increased to $4.1 million due to higher spending on R&D and other expenses. R&D Expenses were $873,012 for the quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
News
Satellos Bioscience Receives Orphan Drug Designation from the U.S. FDA for SAT-3153, a First-in-Class Small Molecule Therapeutic for Duchenne Muscular Dystrophy
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.9%
Tags
clinical trial
Stock MSCLF logo
Satellos Bioscience Inc.

OTC:MSCLF

MSCLF Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

MSCLF Stock Data

42.02M
88.57M
17.56%
0.89%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
Toronto